the role of atp-binding cassette transporter a2 in childhood acute lymphoblastic leukemia multidrug resistance

acute lymphoblastic leukemia (all) is one of the most prevalent hematologic malignancies in children. although the cure rate of all has improved over the past decades, the most important reason for all treatment failure is multidrug resistance (mdr) phenomenon. the current study aims to explain the mechanisms involved in multidrug resistance of childhood all, and introduces atp-binding cassette transportera2 (abca2) as an abc transporter gene which may have a high impact on mdr. benefiting from articles published inreputable journals from1994 to date and experiments newly performed by our group, a comprehensive review is written about abca2 and its role in mdr regarding childhood all. abca2 transports drugs from the cytoplasm into the lysosomal compartment, where they may become degraded and exported from the cell. the aforementioned mechanism may contribute to mdr. it has been reported that abca2 may induce resistance to mitoxantrone, estrogen derivatives and estramustine. it is resistant to the aforementioned compounds. furthermore, the overexpression ofabca2 in methotrexate, vinblastine and/or doxorubicin treated jurkat cells are observed in several publications. the recent study of our group showsthatthe overexpression ofabca2 gene in children with all increases the risk of mdr by 15 times. abca2 is the second identified member of the abca abc transporters' subfamily. abca2 gene expression profile is suggested to be an unfavorable prognostic factor in all treatment. better understanding of the mdr mechanisms and the factors involved may improve the therapeutic outcome of all by modifying the treatment protocols.